The Science of Medical Marijuana Topicals: Transdermal Absorption, Local Effects, and Arthritis Applications

Medical marijuana topicals are everywhere — creams, balms, patches, lotions, salves. Walk into any Florida dispensary and you will find an entire section devoted to them. Patients love them because they seem simple: put it where it hurts, skip the psychoactive effects, no smoke, no edibles, no complicated dosing.

But how much of this is real pharmacology, and how much is wishful thinking? The answer requires understanding something that most product labels do not explain: the difference between topical and transdermal delivery, the challenge of getting cannabinoids through skin, and what actually happens when a cannabinoid cream reaches inflamed tissue.

The Skin Barrier Problem

Your skin is designed to keep things out. The outermost layer — the stratum corneum — is a remarkably effective barrier composed of dead skin cells embedded in a lipid matrix. Think of it as a brick wall: the dead cells are the bricks, and the lipid matrix is the mortar.

For any drug to work through the skin, it needs to penetrate this barrier. The ideal characteristics for transdermal drug delivery are:

• Molecular weight under 500 Daltons. Smaller molecules pass through more easily.
• Moderate lipophilicity. The compound needs to be fat-soluble enough to pass through the lipid matrix but water-soluble enough to eventually reach the aqueous environment of living tissue.
• Low melting point. This correlates with better skin penetration.

Now here is the challenge: THC has a molecular weight of 314 Daltons (good), but it is extremely lipophilic — it loves fat and hates water. This means THC penetrates the lipid-rich stratum corneum relatively well but then gets stuck. It accumulates in the outer skin layers rather than passing through to deeper tissues or the bloodstream.

CBD has similar properties — molecular weight of 314 Daltons, high lipophilicity. The same barrier issue applies.

A 2004 study by Stinchcomb et al. in Pharmaceutical Research quantified this problem: steady-state flux of THC through human skin was approximately 6.3 micrograms per square centimeter per hour. This is a very low rate — far below what most oral or inhaled doses deliver.

Topical vs. Transdermal: A Critical Distinction

Most people use these terms interchangeably, but they describe fundamentally different things:

Topical Products

Topical products are designed to work locally. The cannabinoids penetrate the skin enough to reach receptors in the epidermis, dermis, and immediately underlying tissue, but they do not reach the systemic bloodstream in meaningful quantities.

What this means: A topical cream applied to your knee delivers cannabinoids to the knee area. It does not produce psychoactive effects, will not show up on a drug test (with rare exceptions at very high doses), and does not interact with systemic medications.

Products: Creams, lotions, balms, salves, ointments. These are the most common dispensary topicals.

Transdermal Products

Transdermal products are designed to push cannabinoids through the skin and into the bloodstream. They use penetration enhancers, specialized formulations, or physical mechanisms to overcome the skin barrier.

What this means: A transdermal patch delivers cannabinoids systemically. It can produce psychoactive effects (if THC-containing), will show up on drug tests, and may interact with other medications.

Products: Transdermal patches, some specialized gels with penetration enhancers.

The distinction is critical because the claims made about topical products often implicitly assume transdermal-level penetration, which standard creams and balms simply do not achieve.

What the Research Shows About Local Effects

Despite the penetration challenges, there is evidence that topical cannabinoids have real local effects:

CB1 and CB2 Receptors in the Skin

Your skin is rich in cannabinoid receptors. A 2005 study by Stander et al. published in Experimental Dermatology identified:

• CB1 receptors on keratinocytes, hair follicles, sebaceous glands, and sensory nerve fibers.
• CB2 receptors on keratinocytes, immune cells in the skin, and sebaceous glands.
• TRPV1 receptors (which CBD and other cannabinoids activate) on sensory nerve fibers and keratinocytes.

This means cannabinoids do not need to reach deep tissues or the bloodstream to interact with relevant biological targets. The skin itself is a target organ with its own endocannabinoid system.

Peripheral Nerve Effects

Pain-sensing nerve fibers in the skin express both CB1 and CB2 receptors. A 2016 study by Hohmann and Suplita in Pain demonstrated that peripheral cannabinoid receptor activation can reduce pain signaling independently of central nervous system effects. In other words, cannabinoids acting at the skin level can reduce local pain without the compound ever reaching the brain.

Anti-Inflammatory Effects

Topical CBD has demonstrated anti-inflammatory effects in skin models:

• Reduction of pro-inflammatory cytokines (TNF-alpha, IL-6) in skin tissue.
• Modulation of keratinocyte inflammatory responses.
• Reduction of reactive oxygen species in skin tissue.

A 2019 study by Palmieri et al. in La Clinica Terapeutica found that topical CBD ointment significantly improved skin conditions in 20 patients with psoriasis, atopic dermatitis, and scarring, reducing inflammatory markers and improving quality of life measures.

The Arthritis Data

This is where the clinical relevance becomes clearest for topical medical marijuana.

Preclinical Evidence

The landmark preclinical study was published by Hammell et al. in the European Journal of Pain in 2016. In a rat model of arthritis:

• Topical CBD gel applied to the affected joint reduced joint swelling by 50% at the optimal dose.
• Pain-related behaviors (limb posture, weight bearing) significantly improved.
• Pro-inflammatory cytokines in joint tissue decreased.
• No psychoactive effects were observed, and plasma CBD levels remained very low, confirming local rather than systemic action.
• The effective dose was 6.2 to 62 mg/day applied topically.

This study was important because it demonstrated three things simultaneously: CBD can penetrate skin in sufficient quantity to affect underlying joint inflammation, the effect is local rather than systemic, and the anti-inflammatory and analgesic effects are robust.

Human Studies

The Creighton University Study (2019). A study presented at the American Academy of Dermatology found that a topical CBD product improved pain and cold sensations in patients with peripheral neuropathy in the lower extremities, with 29 of 29 patients reporting improvement.

The Australian Arthritis Study (2022). A randomized, double-blind, placebo-controlled trial by Vela et al. published in Pain evaluated topical CBD for hand osteoarthritis and psoriatic arthritis:

• The CBD group showed greater improvement in worst pain scores at 12 weeks compared to placebo, though the primary endpoint did not reach statistical significance.
• Functional outcomes were mixed.
• The study highlighted the need for optimized formulations and higher concentrations.

Ongoing trials. Several randomized controlled trials of topical cannabinoids for osteoarthritis and rheumatoid arthritis are currently underway, including studies using enhanced-penetration formulations.

Formulation Science: Why the Vehicle Matters

The cream, gel, or ointment that carries the cannabinoid is not just filler — it fundamentally determines how much active compound reaches the target tissue.

Penetration Enhancers

Several approaches can improve cannabinoid skin penetration:

• Chemical enhancers: Compounds like oleic acid, terpenes (limonene, eucalyptol), and propylene glycol can disrupt the stratum corneum and improve penetration by 2 to 10 fold.
• Ethanol: A common pharmaceutical penetration enhancer. Some topical formulations use ethanol-containing vehicles.
• Liposomes and nanoparticles: Encapsulating cannabinoids in lipid nanoparticles can dramatically improve delivery. A 2022 study demonstrated that nano-encapsulated CBD achieved 5 to 8 times higher skin concentrations than conventional formulations.
• Supersaturation: Formulations where the cannabinoid concentration exceeds its solubility in the vehicle drive higher flux through the skin.

What to Look for in a Product

Not all topicals are created equal. When evaluating dispensary products:

• Concentration matters. Products with less than 100 mg of total cannabinoids per container may have insufficient active ingredient to produce meaningful effects when spread over a joint or muscle area.
• The base formulation matters. Ointments (petroleum-based) generally provide better occlusion and penetration than water-based lotions.
• Added penetration enhancers. Look for formulations that include menthol, camphor, or other compounds known to enhance skin penetration. Many "medicated" topicals include these, which may contribute to their perceived efficacy beyond just the cannabinoid content.
• Full-spectrum vs. isolate. Full-spectrum topicals contain terpenes (like beta-caryophyllene, which directly activates CB2 receptors) that may contribute to local anti-inflammatory effects independently of the primary cannabinoid.

Who Benefits Most From Topicals?

Based on the available evidence and clinical experience, medical marijuana topicals are most appropriate for:

Localized arthritis pain. Osteoarthritis in the hands, knees, and other superficial joints is the strongest indication. The inflamed tissue is close enough to the skin surface for topically applied cannabinoids to reach relevant receptors.

Localized muscle pain and tension. Post-exercise soreness, muscle spasm, and myofascial pain in accessible areas.

Peripheral neuropathy. Particularly in the hands and feet, where the affected nerves are near the skin surface.

Skin conditions. Psoriasis, eczema, and contact dermatitis may benefit from the anti-inflammatory and barrier-restoring effects of topical cannabinoids.

Patients who want to avoid systemic effects. For patients concerned about psychoactivity, drug testing, or medication interactions, topicals offer a way to use medical marijuana with minimal systemic exposure.

Topicals are less likely to be effective for:

• Deep joint or spinal pain where the target tissue is far from the skin surface.
• Diffuse conditions like fibromyalgia where the pain is widespread.
• Conditions requiring systemic cannabinoid levels (anxiety, insomnia, nausea).

Practical Guidance

At CORAL, Dr. Kim includes topical products in the treatment discussion when appropriate. Practical tips:

Apply generously. Thin applications may not deliver sufficient cannabinoids. The Hammell study used relatively generous amounts scaled to body surface area.

Give it time. Unlike inhaled cannabis (onset in minutes), topicals may take 30 to 90 minutes to produce noticeable effects as the cannabinoids slowly penetrate the skin.

Reapply regularly. The effect of topicals is not sustained for 24 hours. Most patients need to reapply every 4 to 8 hours for consistent relief.

Consider occlusion. Covering the application area with a bandage or wrap can increase penetration by maintaining moisture and preventing evaporation of the vehicle.

Combine with systemic products when needed. Topicals can be used alongside oral or inhaled medical marijuana for comprehensive pain management. They address different aspects of the pain pathway.

Track your results. Because the evidence base is still developing, your personal experience is important data. Note which products, concentrations, application sites, and frequencies work best for you.

Want to discuss whether medical marijuana topicals might help with your pain? [Start your evaluation at coral.clinic/start](https://coral.clinic/start).